Skip to main content
Erschienen in: Infection 6/2014

01.12.2014 | Original Paper

Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort

verfasst von: R. Leistner, S. Gürntke, C. Sakellariou, L. A. Denkel, A. Bloch, P. Gastmeier, F. Schwab

Erschienen in: Infection | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The burden of extended-spectrum beta-lactamase (ESBL)-positive Enterobacteriaceae (ESBL-E) is growing worldwide. We aimed to determine the financial disease burden attributable to ESBL-positive species in cases of bloodstream infection (BSI) due to K. pneumoniae and E. coli.

Methods

We conducted a cohort study on patients with BSI due to K. pneumoniae or E. coli between 2008 and 2011 in our institution. Data were collected on true hospital costs, length of stay (LOS), basic demographic parameters, underlying diseases as Charlson comorbidity index (CCI) and ESBL positivity of the pathogens. Multivariable regression analysis on hospital costs and length of stay was performed.

Results

Overall we found 1,851 consecutive cases of ESBL-E BSI, 352 (19.0 %) cases of K. pneumoniae BSI and 1,499 (81.0 %) cases of E. coli BSI. Sixty-six of E. coli BSI (18.8 %) and 178 of K. pneumoniae BSI (11.9 %) cases were due to ESBL-positive isolates, respectively (p = 0.001). 830 (44.8 %) cases were hospital-onset, 215 (61.1 %) of the K. pneumoniae and 615 (41.0 %) of the E. coli cases (p < 0.001). In-hospital mortality was overall 19.8, 25.0 % in K. pneumoniae cases and 18.5 % in E. coli cases (p = 0.006). Increased hospital costs and length of stay were significantly associated to BSI with ESBL-positive K. pneumoniae.

Conclusion

In contrast to BSI due to ESBL-positive E. coli, cases of ESBL-positive K. pneumoniae BSI were associated with significantly increased costs and length of stay. Infection prevention measures should differentiate between both pathogens.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) Stockholm: ECDC. 2013. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) Stockholm: ECDC. 2013.
2.
Zurück zum Zitat Savard P, Perl TM. A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings. Curr Opin Infect Dis. 2012;25:371–7.PubMedCrossRef Savard P, Perl TM. A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings. Curr Opin Infect Dis. 2012;25:371–7.PubMedCrossRef
3.
Zurück zum Zitat Goddard S, Muller MP. The efficacy of infection control interventions in reducing the incidence of extended-spectrum beta-lactamase-positive Enterobacteriaceae in the nonoutbreak setting: a systematic review. Am J Infect Control. 2011;39:599–601.PubMedCrossRef Goddard S, Muller MP. The efficacy of infection control interventions in reducing the incidence of extended-spectrum beta-lactamase-positive Enterobacteriaceae in the nonoutbreak setting: a systematic review. Am J Infect Control. 2011;39:599–601.PubMedCrossRef
4.
Zurück zum Zitat Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20:1–55.PubMedCrossRef Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20:1–55.PubMedCrossRef
5.
Zurück zum Zitat Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, et al. Costs of bloodstream infections caused by E. coli and influence of extended-spectrum-beta-lactamase positivity and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54:4085–91.PubMedCentralPubMedCrossRef Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, et al. Costs of bloodstream infections caused by E. coli and influence of extended-spectrum-beta-lactamase positivity and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54:4085–91.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Stewardson A, Fankhauser C, De Angelis G, Rohner P, Safran E, Schrenzel J, et al. Burden of bloodstream infection caused by extended-spectrum beta-lactamase-positive Enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model. Infect Control Hosp Epidemiol. 2013;34:133–43.PubMedCrossRef Stewardson A, Fankhauser C, De Angelis G, Rohner P, Safran E, Schrenzel J, et al. Burden of bloodstream infection caused by extended-spectrum beta-lactamase-positive Enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model. Infect Control Hosp Epidemiol. 2013;34:133–43.PubMedCrossRef
7.
Zurück zum Zitat Leistner R, Bloch A, Sakellariou C, Gastmeier P, Schwab F. Costs and length of stay associated with extended-spectrum β-lactamase positivity in cases of E. coli bloodstream infection. J Glob Antimicrob Resist. 2014. Leistner R, Bloch A, Sakellariou C, Gastmeier P, Schwab F. Costs and length of stay associated with extended-spectrum β-lactamase positivity in cases of E. coli bloodstream infection. J Glob Antimicrob Resist. 2014.
8.
Zurück zum Zitat Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-positive Enterobacteriaceae. Antimicrob Agents Chemother. 2006;50:1257–62.PubMedCentralPubMedCrossRef Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-positive Enterobacteriaceae. Antimicrob Agents Chemother. 2006;50:1257–62.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Hilty M, Betsch BY, Bogli-Stuber K, Heiniger N, Stadler M, Kuffer M, et al. Transmission dynamics of extended-spectrum beta-lactamase-positive Enterobacteriaceae in the tertiary care hospital and the household setting. Clin Infect Dis. 2012;55:967–75.PubMedCentralPubMedCrossRef Hilty M, Betsch BY, Bogli-Stuber K, Heiniger N, Stadler M, Kuffer M, et al. Transmission dynamics of extended-spectrum beta-lactamase-positive Enterobacteriaceae in the tertiary care hospital and the household setting. Clin Infect Dis. 2012;55:967–75.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Tschudin-Sutter S, Frei R, Dangel M, Stranden A, Widmer AF. Rate of transmission of extended-spectrum beta-lactamase-positive Enterobacteriaceae without contact isolation. Clin Infect Dis. 2012;55:1505–11.PubMedCrossRef Tschudin-Sutter S, Frei R, Dangel M, Stranden A, Widmer AF. Rate of transmission of extended-spectrum beta-lactamase-positive Enterobacteriaceae without contact isolation. Clin Infect Dis. 2012;55:1505–11.PubMedCrossRef
11.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef
12.
Zurück zum Zitat Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83.PubMedCentralPubMedCrossRef Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sorensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol. 2011;11:83.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Clinical and Laboratorical Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratorical Standards Institute (CLSI), Wayne, PA, USA [serial on the Internet]. 2012; Twenty-second Informational Supplement M100–S22. Clinical and Laboratorical Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratorical Standards Institute (CLSI), Wayne, PA, USA [serial on the Internet]. 2012; Twenty-second Informational Supplement M100–S22.
14.
Zurück zum Zitat Hu B, Ye H, Xu Y, Ni Y, Hu Y, Yu Y, et al. Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) positive bacteria in China. Curr Med Res Opin. 2010;26:1443–9.PubMedCrossRef Hu B, Ye H, Xu Y, Ni Y, Hu Y, Yu Y, et al. Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) positive bacteria in China. Curr Med Res Opin. 2010;26:1443–9.PubMedCrossRef
15.
Zurück zum Zitat Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-positive E. coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006;27:1226–32.PubMedCrossRef Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-positive E. coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006;27:1226–32.PubMedCrossRef
16.
Zurück zum Zitat de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to E. coli resistant to third-generation cephalosporins. J Antimicrob Chemother. 2011;66:398–407.PubMedCrossRef de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to E. coli resistant to third-generation cephalosporins. J Antimicrob Chemother. 2011;66:398–407.PubMedCrossRef
17.
Zurück zum Zitat Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase positivity in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60:913–20.PubMedCrossRef Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase positivity in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60:913–20.PubMedCrossRef
18.
Zurück zum Zitat Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJ. Colonization and infection with extended spectrum beta-lactamase positive Enterobacteriaceae in high-risk patients—review of the literature from a clinical perspective. Crit Rev Microbiol. 2014. Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJ. Colonization and infection with extended spectrum beta-lactamase positive Enterobacteriaceae in high-risk patients—review of the literature from a clinical perspective. Crit Rev Microbiol. 2014.
Metadaten
Titel
Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort
verfasst von
R. Leistner
S. Gürntke
C. Sakellariou
L. A. Denkel
A. Bloch
P. Gastmeier
F. Schwab
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 6/2014
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-014-0670-9

Weitere Artikel der Ausgabe 6/2014

Infection 6/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.